Page last updated: 2024-08-18

pyrroles and Psoriasis Arthropathica

pyrroles has been researched along with Psoriasis Arthropathica in 43 studies

Research

Studies (43)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	35 (81.40)	24.3611
2020's	8 (18.60)	2.80

Authors

Authors	Studies
Choy, EH; Dews, SA; Galloway, J; Raine, T; Rivett, L; Roberts, J	1
Bacci, ED; Bushmakin, AG; Cappelleri, JC; Coates, LC; Fallon, L; Gladman, DD; Helliwell, PS; Wu, J	1
Bingham, CO; Brault, Y; Dougados, M; Fallon, L; Kessouri, M; Roychoudhury, S; Taylor, PC; Wang, L	1
Abdulrahim, H; Adebajo, AO; Sharlala, H	1
Krüger, K	1
Bertoldi, I; Orsolini, G; Rossini, M	1
Caso, F; Chimenti, MS; Costa, L; Del Puente, A; Giacomelli, R; Girolimetto, N; Navarini, L; Ruscitti, P; Scarpa, R	1
Boehncke, WH; Graham, D; Gratacós, J; Hsu, MA; Merola, JF; Nash, P; Papp, KA; Thaçi, D; Wang, C; Wu, J; Young, P	1
Dörner, T	1
Gómez Castro, S; González Fernández, CM; Gratacós Masmitjà, J; Rebollo Laserna, FJ	1
Abdel, MP; Brause, B; Chen, AF; Dasa, V; George, M; Gewurz-Singer, O; Giles, JT; Gililland, J; Goodman, M; Goodman, SM; Guyatt, G; Hurley-Rosenblatt, A; Johnson, B; Kirou, K; Lee, S; Losina, E; MacKenzie, R; Mandl, LA; Michaud, K; Mikuls, T; Miller, AS; Mont, MA; Russell, L; Sah, A; Sculco, P; Singh, JA; Sporer, S; Springer, B; Stryker, L; Turgunbaev, M; Yates, A	2
Benigno, C; Bertolini, N; Caso, F; Caso, P; Chimenti, MS; Costa, L; Del Puente, A; Girolimetto, N; Peluso, R; Perricone, R; Sabbatino, V; Scarpa, R; Tasso, M	1
Tsai, TF; Wang, TS	1
Azevedo, VF; Behrens, F; Blanco, R; Gladman, D; Hendrikx, T; Kanik, KS; Kaszuba, A; Kudlacz, E; Menon, S; Rigby, W; Wang, C	1
Avila-Zapata, F; Cieślak, D; FitzGerald, O; Graham, D; Hall, S; Hendrikx, T; Kanik, KS; Mease, P; Menon, S; Merola, JF; van der Heijde, D; Wang, C	1
Onuora, S	1
McHugh, J	1
Barroso, NS; Furst, DE; Miller, EZ	1
Gladman, D; Mease, P	1
Aletaha, D; Kerschbaumer, A; Smolen, JS	1
Berekmeri, A; Helliwell, P; Mahmood, F; Wittmann, M	1
Elman, SA; Merola, JF; Weinblatt, M	1
Coates, LC; Elaine Husni, M; FitzGerald, O; Helliwell, P; Hendrikx, T; Hsu, MA; Kanik, KS; Kudlacz, E; Nash, P; Soriano, ER; Wu, J	1
Coates, LC; Deal, C; Deodhar, A; Dubreuil, M; Dunham, J; Gladman, DD; Gottlieb, A; Guyatt, G; Husni, ME; Jonsson, AH; Kenny, S; Kwan-Morley, J; Lin, J; Magrey, M; Marchetta, P; Mease, PJ; Merola, JF; Miner, J; Nowell, WB; Ogdie, A; Orbai, AM; Reddy, SM; Reston, J; Ritchlin, CT; Scher, JU; Shah, AA; Siaton, B; Siegel, E; Siegel, M; Singh, JA; Smith, BJ; Sullivan, N; Turgunbaev, M; Turner, AS; Van Voorhees, AS; Walsh, JA	1
Dressler, C; Eisert, L; Nast, A; Pham, PA; Werner, RN	1
Cappelleri, JC; Covarrubias-Cobos, JA; de Vlam, K; Gladman, DD; Graham, D; Hendrikx, T; Hsu, MA; Mease, PJ; Strand, V; Wang, C	1
Cappelleri, JC; Chen, L; Covarrubias-Cobos, JA; de Vlam, K; Gladman, DD; Hendrikx, T; Hsu, MA; Kudlacz, E; Mease, PJ; Strand, V; Wu, J	1
Lee, YH; Song, GG	1
Fallon, L; FitzGerald, O; Gladman, DD; Graham, D; Kavanaugh, A; van der Heijde, D; Wang, C	1
Deeks, ED; Paik, J	1
Charles-Schoeman, C; DeMasi, R; Gladman, DD; Graham, D; Jones, T; McInnes, IB; Nurmohamed, M; Thiers, B; Veale, DJ; Wang, C; Wolk, R	1
Deng, C; Kanik, KS; Menon, S; Nicholas, T; Wang, Q; Xie, R	1
Han, G	1
Fearon, U; Gao, W; McCormick, J; McGarry, T; Orr, C; Veale, DJ	1
Asahina, A; Etoh, T; Igarashi, A; Imafuku, S; Nagaoka, M; Ohtsuki, M; Saeki, H; Shibasaki, Y; Tomochika, Y; Toyoizumi, S	1
Warren, RB; Yiu, ZZ	1
Gerdes, S; Gläser, R; Mrowietz, U; Schröder, O	1
Kerdel, FA	1
Braun, J	1
Abria, C; Raychaudhuri, SK; Raychaudhuri, SP	1
Fearon, U; Gao, W; McGarry, T; Veale, DJ	1

Reviews

18 review(s) available for pyrroles and Psoriasis Arthropathica

Article	Year
Herpes zoster and Janus kinase inhibition in rheumatology and gastroenterology patients: managing risk and vaccination. Clinical and experimental rheumatology, 2022, Volume: 40, Issue:7 Topics: Arthritis, Psoriatic; Arthritis, Rheumatoid; Colitis, Ulcerative; Gastroenterology; Herpes Zoster; Humans; Janus Kinase Inhibitors; Janus Kinases; Pyrroles; Rheumatology; Vaccination	2022
An evaluation of tofacitinib for the treatment of psoriatic arthritis. Expert opinion on pharmacotherapy, 2019, Volume: 20, Issue:16 Topics: Arthritis, Psoriatic; Clinical Trials as Topic; Dose-Response Relationship, Drug; Half-Life; Humans; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles	2019
[Role of janus kinase inhibitors in the treatment of rheumatic diseases]. Der Internist, 2019, Volume: 60, Issue:11 Topics: Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Azetidines; Drug Therapy, Combination; Humans; Janus Kinase Inhibitors; Methotrexate; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome	2019
Osteoimmunology in rheumatoid and psoriatic arthritis: potential effects of tofacitinib on bone involvement. Clinical rheumatology, 2020, Volume: 39, Issue:3 Topics: Arthritis, Psoriatic; Arthritis, Rheumatoid; Bone and Bones; Bone Remodeling; Humans; Immune System; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction; STAT Transcription Factors	2020
Targeted synthetic pharmacotherapy for psoriatic arthritis: state of the art. Expert opinion on pharmacotherapy, 2020, Volume: 21, Issue:7 Topics: Administration, Oral; Antirheumatic Agents; Arthritis, Psoriatic; Azetidines; Humans; Janus Kinases; Molecular Targeted Therapy; Phosphodiesterase 4 Inhibitors; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides; Thalidomide; Treatment Outcome	2020
Efficacy of Tofacitinib in the Treatment of Psoriatic Arthritis: A Systematic Review. Advances in therapy, 2021, Volume: 38, Issue:2 Topics: Antirheumatic Agents; Arthritis, Psoriatic; Humans; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome	2021
2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. The Journal of arthroplasty, 2017, Volume: 32, Issue:9 Topics: Antirheumatic Agents; Arthritis, Juvenile; Arthritis, Psoriatic; Arthritis, Rheumatoid; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Elective Surgical Procedures; Glucocorticoids; Humans; Lupus Erythematosus, Systemic; Perioperative Care; Piperidines; Pyrimidines; Pyrroles; Rheumatic Diseases; Rheumatology; Spondylarthritis; Spondylitis, Ankylosing; Surgeons; United States	2017
Small molecule therapy for managing moderate to severe psoriatic arthritis. Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:15 Topics: Antirheumatic Agents; Arthritis, Psoriatic; Humans; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Severity of Illness Index; Small Molecule Libraries; Thalidomide; Treatment Outcome	2017
Tofacitinib in psoriatic arthritis. Immunotherapy, 2017, Volume: 9, Issue:14 Topics: Animals; Arthritis, Psoriatic; Clinical Trials as Topic; Humans; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles	2017
Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert review of clinical immunology, 2018, Volume: 14, Issue:9 Topics: Antirheumatic Agents; Arthritis, Psoriatic; Clinical Trials as Topic; Drug Approval; Humans; Janus Kinases; Nasopharyngitis; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles	2018
Targeted therapies for psoriatic arthritis: an update for the dermatologist. Seminars in cutaneous medicine and surgery, 2018, Volume: 37, Issue:3 Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Psoriatic; Dermatologic Agents; Dermatology; Humans; Interleukin-17; Interleukin-23; Janus Kinase Inhibitors; Molecular Targeted Therapy; Phosphodiesterase 4 Inhibitors; Piperidines; Pyrimidines; Pyrroles; Severity of Illness Index; Thalidomide; Tumor Necrosis Factor-alpha	2018
Time until onset of action when treating psoriatic arthritis: meta-analysis and novel approach of generating confidence intervals. Rheumatology international, 2019, Volume: 39, Issue:4 Topics: Adalimumab; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Psoriatic; Confidence Intervals; Humans; Infliximab; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Thalidomide; Time Factors; Treatment Outcome; Tumor Necrosis Factor Inhibitors; Ustekinumab	2019
Comparison of the Efficacy and Safety of Tofacitinib and Apremilast in Patients with Active Psoriatic Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. Clinical drug investigation, 2019, Volume: 39, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Bayes Theorem; Humans; Network Meta-Analysis; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome	2019
Tofacitinib: A Review in Psoriatic Arthritis. Drugs, 2019, Volume: 79, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Psoriatic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome; Young Adult	2019
Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long-Term Extension Studies. Arthritis care & research, 2019, Volume: 71, Issue:10 Topics: Arthritis, Psoriatic; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Humans; Incidence; Lipids; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome	2019
In the pipeline for psoriasis: upcoming psoriasis treatments. Cutis, 2014, Volume: 93, Issue:3 Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic; Certolizumab Pegol; Etanercept; Humans; Immunoglobulin Fab Fragments; Immunoglobulin G; Immunosuppressive Agents; Infliximab; Interleukin-12 Subunit p40; Janus Kinases; Nitriles; Piperidines; Polyethylene Glycols; Protein Kinase Inhibitors; Psoriasis; Pyrazoles; Pyrimidines; Pyrroles; Receptors, Interleukin-17; Receptors, Tumor Necrosis Factor; Tumor Necrosis Factor-alpha; Ustekinumab	2014
Novel Oral Therapies for Psoriasis and Psoriatic Arthritis. American journal of clinical dermatology, 2016, Volume: 17, Issue:3 Topics: Adamantane; Adenosine; Adenosine A3 Receptor Antagonists; Administration, Oral; Arthritis, Psoriatic; Azetidines; Biological Factors; Biological Therapy; Clinical Trials as Topic; Humans; Isonicotinic Acids; Janus Kinases; Niacinamide; Phosphodiesterase 4 Inhibitors; Piperidines; Protein Kinase Inhibitors; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Receptors, Lysosphingolipid; rho-Associated Kinases; Sulfonamides; Thalidomide; Thiazoles	2016
New targets in psoriatic arthritis. Rheumatology (Oxford, England), 2016, Volume: 55, Issue:suppl 2 Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Psoriatic; Cyclophosphamide; Etanercept; Humans; Infliximab; Methotrexate; Molecular Targeted Therapy; Phosphodiesterase 4 Inhibitors; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Sulfasalazine; Thalidomide; Ustekinumab	2016

Trials

9 trial(s) available for pyrroles and Psoriasis Arthropathica

Article	Year
The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis. RMD open, 2022, Volume: 8, Issue:2 Topics: Adalimumab; Arthritis, Psoriatic; Arthritis, Rheumatoid; Bayes Theorem; C-Reactive Protein; Humans; Inflammation; Pyrroles; Treatment Outcome	2022
Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors. The New England journal of medicine, 2017, 10-19, Volume: 377, Issue:16 Topics: Administration, Oral; Adult; Alanine Transaminase; Antirheumatic Agents; Arthritis, Psoriatic; Aspartate Aminotransferases; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Janus Kinases; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Failure; Tumor Necrosis Factor-alpha	2017
Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. The New England journal of medicine, 2017, 10-19, Volume: 377, Issue:16 Topics: Adalimumab; Administration, Oral; Adult; Antirheumatic Agents; Arthritis, Psoriatic; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Janus Kinases; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles	2017
Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease. Arthritis research & therapy, 2018, Oct-29, Volume: 20, Issue:1 Topics: Adalimumab; Antirheumatic Agents; Arthritis, Psoriatic; Drug Delivery Systems; Female; Humans; Injections, Subcutaneous; Janus Kinase Inhibitors; Longitudinal Studies; Male; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome	2018
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. RMD open, 2019, Volume: 5, Issue:1 Topics: Adalimumab; Adult; Antirheumatic Agents; Arthritis, Psoriatic; Female; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome	2019
Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond. RMD open, 2019, Volume: 5, Issue:1 Topics: Arthritis, Psoriatic; Biomarkers; Female; Humans; Male; Patient Reported Outcome Measures; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor Inhibitors	2019
Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab. The Journal of rheumatology, 2019, Volume: 46, Issue:9 Topics: Adalimumab; Adult; Antirheumatic Agents; Arthritis, Psoriatic; C-Reactive Protein; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Risk Factors; Treatment Outcome	2019
Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis . International journal of clinical pharmacology and therapeutics, 2019, Volume: 57, Issue:9 Topics: Adolescent; Adult; Aged; Arthritis, Psoriatic; Female; Humans; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Young Adult	2019
Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study. The Journal of dermatology, 2016, Volume: 43, Issue:8 Topics: Administration, Oral; Adult; Aged; Arthritis, Psoriatic; Double-Blind Method; Female; Herpes Zoster; Humans; Japan; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome	2016

Other Studies

16 other study(ies) available for pyrroles and Psoriasis Arthropathica

Article	Year
Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo. Arthritis research & therapy, 2022, 02-09, Volume: 24, Issue:1 Topics: Adalimumab; Antirheumatic Agents; Arthritis, Psoriatic; Humans; Patient Reported Outcome Measures; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome	2022
Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies. Journal of the European Academy of Dermatology and Venereology : JEADV, 2020, Volume: 34, Issue:12 Topics: Adult; Arthritis, Psoriatic; Double-Blind Method; Humans; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Quality of Life; Treatment Outcome	2020
Lessons from tofacitinib in patients with cardiovascular risk factors: increased pulmonary embolism or isolated (thrombotic) pulmonary occlusion rates? Annals of the rheumatic diseases, 2020, Volume: 79, Issue:11 Topics: Arthritis, Psoriatic; Arthritis, Rheumatoid; Humans; Incidence; Piperidines; Psoriasis; Pulmonary Embolism; Pyrimidines; Pyrroles	2020
2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Arthritis & rheumatology (Hoboken, N.J.), 2017, Volume: 69, Issue:8 Topics: Antirheumatic Agents; Arthritis, Juvenile; Arthritis, Psoriatic; Arthritis, Rheumatoid; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Biological Products; Glucocorticoids; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Orthopedics; Perioperative Care; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rheumatic Diseases; Rheumatology; Societies, Medical; Spondylitis, Ankylosing; United States	2017
Spondyloarthropathies: Tofacitinib shows promise in PsA trials. Nature reviews. Rheumatology, 2017, 12-19, Volume: 14, Issue:1 Topics: Arthritis, Psoriatic; Humans; Piperidines; Pyrimidines; Pyrroles; Spondylarthropathies	2017
Epidemiology: Arthritis more common than expected. Nature reviews. Rheumatology, 2017, 12-19, Volume: 14, Issue:1 Topics: Arthritis; Arthritis, Psoriatic; Humans; Piperidines; Pyrimidines; Pyrroles	2017
A Case Series on Patients on Tofacitinib in Combination With a Biologic. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2018, Volume: 24, Issue:6 Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Janus Kinase 3; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Severity of Illness Index; Treatment Outcome	2018
Tofacitinib for Psoriatic Arthritis. The New England journal of medicine, 2018, 02-22, Volume: 378, Issue:8 Topics: Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Humans; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome	2018
Tofacitinib for Psoriatic Arthritis. The New England journal of medicine, 2018, 02-22, Volume: 378, Issue:8 Topics: Arthritis, Psoriatic; Piperidines; Pyrimidines; Pyrroles	2018
Tofacitinib for psoriatic arthritis (PsA) is now approved by the European Commission. Rheumatology (Oxford, England), 2018, Sep-01, Volume: 57, Issue:9 Topics: Arthritis, Psoriatic; Drug Approval; Europe; Humans; Janus Kinase 3; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles	2018
Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis & rheumatology (Hoboken, N.J.), 2019, Volume: 71, Issue:1 Topics: Abatacept; Adalimumab; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Psoriatic; Comorbidity; Diabetes Mellitus; Enthesopathy; Etanercept; Evidence-Based Medicine; Exercise; Glucocorticoids; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Infliximab; Interleukin-12; Interleukin-17; Interleukin-23; Occupational Therapy; Physical Therapy Modalities; Piperidines; Pyrimidines; Pyrroles; Rheumatology; Smoking Cessation; Societies, Medical; Spondylitis; Tumor Necrosis Factor-alpha; Ustekinumab; Weight Loss	2019
Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors. Annals of the rheumatic diseases, 2016, Volume: 75, Issue:1 Topics: Adult; Arthritis, Psoriatic; Cell Movement; Cells, Cultured; Female; Fibroblasts; Humans; Inflammation Mediators; Janus Kinase 3; Male; Middle Aged; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction; STAT Transcription Factors; Synovial Membrane; Synovitis; Tissue Culture Techniques	2016
Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not of Plaque Psoriasis with Tofacitinib in a Young Woman. Acta dermato-venereologica, 2017, 02-08, Volume: 97, Issue:2 Topics: Adolescent; Alopecia; Alopecia Areata; Arthritis, Psoriatic; Female; Humans; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retreatment	2017
Update on TNF Inhibitors. Seminars in cutaneous medicine and surgery, 2016, Volume: 35, Issue:4 Suppl 4 Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic; Cardiovascular Diseases; Certolizumab Pegol; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Dermatologic Agents; Etanercept; Humans; Infliximab; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome; Tumor Necrosis Factor-alpha; Ustekinumab	2016
Regulatory role of the JAK STAT kinase signalling system on the IL-23/IL-17 cytokine axis in psoriatic arthritis. Annals of the rheumatic diseases, 2017, Volume: 76, Issue:10 Topics: Arthritis, Psoriatic; Humans; Inflammation; Interleukin-17; Interleukin-23; Janus Kinases; Piperidines; Pyrimidines; Pyrroles	2017
Response to: 'Regulatory role of the JAK STAT kinase signalling system on the IL-23/IL-17 cytokine axis in psoriatic arthritis' by Raychaudhuri Annals of the rheumatic diseases, 2017, Volume: 76, Issue:10 Topics: Arthritis, Psoriatic; Humans; Inflammation; Interleukin-17; Interleukin-23; Janus Kinases; Piperidines; Pyrimidines; Pyrroles	2017